3,000 Shares in iShares Biotechnology ETF (NASDAQ:IBB) Purchased by Oakworth Capital Inc.

Oakworth Capital Inc. acquired a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,000 shares of the financial services provider’s stock, valued at approximately $408,000.

A number of other large investors also recently added to or reduced their stakes in the business. Tyche Wealth Partners LLC bought a new stake in shares of iShares Biotechnology ETF in the 4th quarter valued at about $802,000. Imprint Wealth LLC bought a new stake in iShares Biotechnology ETF in the fourth quarter valued at approximately $202,000. SFI Advisors LLC acquired a new stake in iShares Biotechnology ETF in the fourth quarter worth $564,000. Flputnam Investment Management Co. bought a new position in shares of iShares Biotechnology ETF during the fourth quarter worth $204,000. Finally, Bourgeon Capital Management LLC bought a new position in shares of iShares Biotechnology ETF during the fourth quarter worth $476,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

IBB opened at $125.89 on Thursday. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $141.16. The company has a fifty day simple moving average of $135.48 and a 200 day simple moving average of $129.55.

iShares Biotechnology ETF Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 27th. Shareholders of record on Friday, March 22nd were issued a $0.126 dividend. The ex-dividend date was Thursday, March 21st. This represents a $0.50 annualized dividend and a dividend yield of 0.40%.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.